Alamar upsizes IPO

Alamar Biosciences priced an upsized initial public offering at $17 a share on April 17, selling 11.25 million shares to raise about $191.3 million. (renaissancecapital.com, sec.gov) The Fremont, California, company had marketed 9.4 million shares at $15 to $17 earlier in the week, so the final deal added about 20% more stock and priced at the top of the range. Alamar has applied to list on the Nasdaq Global Market under the ticker ALMR. (renaissancecapital.com, sec.gov) Proteomics is the business of measuring proteins, the molecules that cells make and release as the body changes. Alamar sells tools meant to spot tiny amounts of those proteins in blood and other samples, which researchers use in work on Alzheimer’s disease, Parkinson’s disease and other illnesses. (alamarbio.com, alamarbio.com) Its core products are the NULISA assays and the ARGO instrument, which the company says are built for high-sensitivity protein biomarker analysis. In plain terms, Alamar is trying to make weak biological signals easier to detect, the way a better microphone can pick up a whisper in a noisy room. (alamarbio.com, sec.gov) The company’s April 13 amended prospectus said revenue rose to $74.2 million in 2025 from $25.1 million in 2024, a 195% year-over-year increase. The same filing said Alamar still expected an operating loss for the quarter ended March 31, 2026, underscoring that it remains in expansion mode. (sec.gov, sec.gov) That mix of fast growth and continuing losses is common in life-science tools, where companies spend heavily on instruments, assay menus and sales teams before recurring consumables revenue scales up. Alamar said in January that T. Rowe Price Investment Management and Braidwell participated in an oversubscribed convertible-notes financing, giving it fresh capital even before the IPO. (sec.gov, alamarbio.com) The IPO also lands in a selective market for new issues. Renaissance Capital’s April 17 IPO coverage singled out Alamar as a rare proteomics-related deal to price above its original size, even as many biotech and tools listings have stayed small or delayed. (renaissancecapital.com, renaissancecapital.com) Alamar’s recent product launches have centered on blood-based biomarker panels for neurodegenerative disease research, including assays tied to Alzheimer’s disease and a larger Neuro 220 panel introduced in March. Those products are labeled research use only, which means they are built for lab research rather than cleared as routine diagnostic tests for patients. (alamarbio.com, alamarbio.com) The immediate test is whether public investors keep backing a company that is selling picks and shovels to disease-detection researchers rather than a drug. By pricing at the high end and enlarging the deal, Alamar showed there was enough demand on April 17 to get that bet done. (renaissancecapital.com, sec.gov)